{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:08Z","timestamp":1787028488769,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research C","award":["20K08617"],"award-info":[{"award-number":["20K08617"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. In Japan, the proportion of new patients requiring dialysis due to DKD has remained unchanged over the past five years. Early diagnosis and treatment are extremely important for the prevention of DKD progression. Albuminuria is the most promising biomarker currently available for diagnosing DKD and predicting its prognosis at an early stage; however, it has relatively poor specificity and sensitivity for DKD. Measuring the serum levels of tumor necrosis factor receptors (TNFRs; TNFR1 and TNFR2) is an alternative for predicting the prognosis of patients with CKD, irrespective of their diabetes status. Cardiorenal risk factor management and renin\u2013angiotensin system inhibitor usage are effective in slowing the DKD progression, although the residual risk remains high in patients with DKD. Recently, two classes of antihyperglycemic agents, sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, in addition to nonsteroidal selective mineralocorticoid receptor antagonists, which are less potent blood pressure-lowering and potassium-sparing agents, have emerged as cardiorenal disease-modifying therapies for preventing the DKD progression. This review focused on the SGLT2 inhibitor-based therapeutic strategies that have demonstrated cardiorenal benefits in patients with type 2 diabetes.<\/jats:p>","DOI":"10.3390\/ijms232213749","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T02:34:52Z","timestamp":1667961292000},"page":"13749","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Sodium-Glucose Cotransporter-2 Inhibitors\u2014Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-4433","authenticated-orcid":false,"given":"Tomohito","family":"Gohda","sequence":"first","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-269X","authenticated-orcid":false,"given":"Maki","family":"Murakoshi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.14789\/jmj.2019.65.JMJ19-R16","article-title":"Concept of diabetic kidney disease-paradigm shift from albuminuria-based to GFR-based kidney disease","volume":"65","author":"Gohda","year":"2019","journal-title":"Juntendo Med. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s41100-020-00286-9","article-title":"Annual dialysis data report for 2018, JSDT Renal Data Registry: Survey methods, facility data, incidence, prevalence, and mortality","volume":"6","author":"Nitta","year":"2020","journal-title":"Ren. Replace Ther."},{"key":"ref_3","unstructured":"(2022, September 08). Chapter 11: International Comparison, the 2018 USRDS Annual Data Report. Washington: United States Renal Data System, 2018. Available online: https:\/\/www.usrds.org."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11892-013-0385-9","article-title":"Novel biomarkers for the progression of diabetic nephropathy: Soluble TNF receptors","volume":"13","author":"Gohda","year":"2013","journal-title":"Curr. Diab. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"UKPDS33 (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 837\u2013853.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000454683","article-title":"Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: A systematic review of randomized clinical trials","volume":"136","author":"Walker","year":"2017","journal-title":"Nephron"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"ref_11","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am. J. Manag. Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1681\/ASN.2013091002","article-title":"Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria","volume":"25","author":"Skupien","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1681\/ASN.2011060628","article-title":"Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes","volume":"23","author":"Gohda","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","article-title":"A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes","volume":"25","author":"Niewczas","year":"2019","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"634932","DOI":"10.3389\/fmed.2021.634932","article-title":"Association between kidney function decline and baseline TNFR levels or change ratio in TNFR by febuxostat chiefly in non-diabetic CKD patients with asymptomatic hyperuricemia","volume":"8","author":"Gohda","year":"2021","journal-title":"Front. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"849457","DOI":"10.3389\/fendo.2022.849457","article-title":"Progranulin and its receptor predict kidney function decline in patients with type 2 diabetes","volume":"13","author":"Murakoshi","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.08780621","article-title":"Association between TNF receptors and KIM-1 with kidney outcomes in early-stage diabetic kidney disease","volume":"17","author":"Waijer","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"43520","DOI":"10.1038\/srep43520","article-title":"Circulating TNF receptors 1 and 2 predict mortality in patients with end-stage renal disease undergoing dialysis","volume":"7","author":"Gohda","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1681\/ASN.2021060735","article-title":"Longitudinal TNFR1 and TNFR2 and kidney outcomes: Results from AASK and VA NEPHRON-D","volume":"33","author":"Chen","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2337\/dc21-0300","article-title":"Efficacy and safety of dapagliflozin by baseline glycemic status: A prespecified analysis from the DAPA-CKD trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","article-title":"Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes","volume":"98","author":"Li","year":"2020","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: Results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/CIRCULATIONAHA.121.058103","article-title":"Efficacy and safety of dapagliflozin in type 2 diabetes according to baseline blood pressure: Observations from DECLARE-TIMI 58 trial","volume":"145","author":"Furtado","year":"2022","journal-title":"Circulation"},{"key":"ref_33","first-page":"i847","article-title":"Effeects of dapagliflozin in patients with chronic kidney disease according to background angiotensin-converting enzyme inhibitor and angiotensin receptor blocker dose","volume":"37","author":"Heerspink","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program","volume":"30","author":"Neuen","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2337\/dc21-0076","article-title":"The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58","volume":"44","author":"Mosenzon","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/dom.13579","article-title":"Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers","volume":"21","author":"Heerspink","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the CREDENCE trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with chronic kidney disease","volume":"33","author":"Jongs","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"Kraus","year":"2021","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","article-title":"Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: Insights from DAPA-HF","volume":"146","author":"Adamson","year":"2022","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e020237","DOI":"10.1161\/JAHA.120.020237","article-title":"Clinical implications of estimated glomerular filtration rate dip following sodium-glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes","volume":"10","author":"Xie","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2021.05.005","article-title":"Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: Findings from the randomized CREDENCE trial","volume":"79","author":"Heerspink","year":"2022","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.kint.2021.09.005","article-title":"A pre-specified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function","volume":"101","author":"Heerspink","year":"2022","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/dom.13754","article-title":"Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials","volume":"21","author":"Gilbert","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.ekir.2021.02.038","article-title":"Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort","volume":"6","author":"Hougen","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: A randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Green, J.B., Mottl, A.K., Bakris, G., Heerspink, H.J.L., Mann, J.F.E., McGill, J.B., Nangaku, M., Rossing, P., Scott, C., and Gay, A. Design of the combination effect of fInerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE). Nephrol. Dial. Transpl., 2022.","DOI":"10.1093\/ndt\/gfac198"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/2211-5463.13014","article-title":"The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice","volume":"10","author":"Li","year":"2020","journal-title":"FEBS Open Bio."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: An update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-019-0903-4","article-title":"Class effects of SGLT2 inhibitors on cardiorenal outcomes","volume":"18","author":"Kluger","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1440-1797.2010.01291.x","article-title":"Functional renal reserve capacity in different stages of chronic kidney disease","volume":"15","author":"Barai","year":"2010","journal-title":"Nephrology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/ejhf.2334","article-title":"Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial","volume":"23","author":"Packer","year":"2021","journal-title":"Eur. J. Heart Fail."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/13749\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:52Z","timestamp":1760145172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/13749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":66,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232213749"],"URL":"https:\/\/doi.org\/10.3390\/ijms232213749","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]}}}